Navigation Links
BioTrends Announces the Continuation of a Syndicated Report Series: TreatmentTrends: CKD Stages 1-5ND

EXTON, Pa., March 13, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, announces the continuation of the report series entitled TreatmentTrends: Chronic Kidney Disease Stages 1-5 Non-Dialysis. BioTrends plans to field the third wave of this research similarly to the two waves conducted in 2012, with each wave consisting of findings from a quantitative survey with 250 physicians (100 nephrologists, 100 primary care physicians, and 50 endocrinologists). Below are some key findings from the second wave of this report series; these items and others will be tracked in the third wave of research to observe changes over time:

  • The majority of physicians feel that patients are referred to nephrologists too late, nephrologists are significantly more likely than PCPs to feel this way
  • According to nephrologists, the primary reason that PCPs refer CKD patients to nephrologists is based on a high creatinine level or rising creatinine levels
  • For many medication classes, treatment tends to increase as CKD worsens - by Stage 5ND, approximately forty percent of patients are on phosphate binders, approximately forty percent are on oral active Vitamin D, and just over twenty percent are on erythropoiesis-stimulating agents
  • Similar to the first wave of research, physicians tend to report moderate to high interest in Concert Pharmaceutical's CTP-499 and Mitsubishi Tanabe's AST-120
  • (Logo: )

    TreatmentTrends: Chronic Kidney Disease Stages 1-5 Non-Dialysis is a report series designed to track physician perception of the CKD-ND patient population, including referral patterns, patient load, current treatments, screening protocols, diagnosis patterns, frequency of comorbidities, unmet needs, and reaction to new products in development. TreatmentTrends: Chronic Kidney Disease Stages 1-5 Non-Dialysis, which is written by BioTrends Research Group nephrology experts, uses feedback provided directly from biotechnology and pharmaceutical organizations as well as nephrology thought leaders. Proprietary questions are solicited from key contacts at appropriate organizations. The third wave of this report will publish by July 3, 2013 with comments and proprietary questions for this wave due on March 22, 2013.

    About BioTrends Research Group
    BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit us at BioTrends is a Decision Resources Group company.

    About Decision Resources Group
    Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

    All company, brand, or product names contained in this document may be trademarks of their respective holders.For more information, contact:BioTrends Research Group, LLCDecision Resources GroupRob Dubman

    Christopher Comfort781-993-2592 

    SOURCE BioTrends Research Group
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
    2. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
    3. PDI, Inc. Announces $17 Million Multi-Year Sales Contract
    4. BD Announces Appointment of Dr. Ellen Strahlman as Chief Medical Officer and Senior Vice President, Research & Development
    5. N30 Pharmaceuticals Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
    6. HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock
    7. Johnson & Johnson Announces Opening of London Innovation Centre
    8. GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2012
    9. Jensen Dental Announces Launch of the Preciso Digital Dentistry Solution; Includes New CAD/CAM Software and Website
    10. MedShape, Inc. Announces New 10mm DynaNail
    11. I-Flow Announces Bus Tour to Educate Care Providers on Acute Surgical Pain Management
    Post Your Comments:
    (Date:11/24/2015)... , 24. November 2015 ... Breathing Pacemaker Systems, ist erfreut, die Berufung ... Consultant bekannt geben zu können. ...   --> Foto - ... (Schweden). Von 1984-1986 war er Fellow ...
    (Date:11/24/2015)... Avery Biomedical Devices (ABD), manufacturer of the ... appointment of Anders Jonzon , MD; Ph.D. as ... Dr. Jonzon is a Physiologist and consultant ... University, Uppsala and Children,s Hospital, Karolinska, Stockholm, ... at the Cardiovascular Institute (UCSF). His research has covered ...
    (Date:11/24/2015)... Inc. (Pink Sheets: ASDS ) ("Ascendant" or the "Company") ... special 1 percent stock dividend on the company,s common stock ... shareholders of record December 7, 2015.  The dividend will be ... --> --> "This ... confidence in Ascendant,s growth strategy as well as the underlying ...
    Breaking Medicine Technology:
    (Date:11/25/2015)... ... November 25, 2015 , ... Castlewood Treatment Center ... with eating disorders as a result of the $20,000 raised at the center’s ... Fox Run Golf Club in Eureka, will help individuals who otherwise might not ...
    (Date:11/25/2015)... PITTSBURGH, PA (PRWEB) , ... November 25, 2015 ... ... to treat my cancer, I found that regular bras were incredibly uncomfortable," said ... I developed this specialized bra." , She developed the patent-pending RECOVERY BRA for ...
    (Date:11/25/2015)... ... 2015 , ... An unlikely combination of recycled plastic shopping ... homeless people to have a more dignified and comfortable night’s sleep. , Residents ... repurposing plastic bags into sleeping mats for the homeless. The project, according ...
    (Date:11/25/2015)... CHICAGO, IL (PRWEB) , ... November 25, 2015 ... ... the cure for Tuberous Sclerosis Complex (TSC), as well as raising public awareness ... people where they need it—presented a third donation of $35,000 to bolster progress ...
    (Date:11/25/2015)... Mateo, CA (PRWEB) , ... November 25, 2015 , ... ... in prizes were awarded to winners of the Create Real Impact awards. California ... creative expression to help stem the tide of distracted and reckless driving, the number ...
    Breaking Medicine News(10 mins):